Information Provided By:
Fly News Breaks for September 27, 2018
AGN, RVNC
Sep 27, 2018 | 06:21 EDT
Mizuho analyst Difei Yang says that while Allergan's (AGN) new data from a Phase 1b trial of higher dose Botox in moderate-to-severe glabellar lines showed better duration relative to the standard dose Botox, Revance Therapeutics (RVNC) remains best positioned to address the long-duration botulinum toxin products market. The analyst believes the weakness in Revance shares during 2018 has created buying opportunities. The analyst reiterates a Buy rating on the stock with a $48 price target.
News For RVNC;AGN From the Last 2 Days
There are no results for your query RVNC;AGN